Intersect ENT Revenue and Competitors

Location

$167.8M

Total Funding

Estimated Revenue & Valuation

  • Intersect ENT's estimated annual revenue is currently $112.4M per year.(i)
  • Intersect ENT received $30.0M in venture funding in February 2013.
  • Intersect ENT's estimated revenue per employee is $698,435
  • Intersect ENT's total funding is $167.8M.

Employee Data

  • Intersect ENT has 161 Employees.(i)
  • Intersect ENT grew their employee count by -8% last year.

Intersect ENT's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$20.3M817%N/AN/A
#2
$8.5M346%N/AN/A
#3
$4.5M18-10%N/AN/A
#4
$8M32-6%N/AN/A
#5
$5.3M210%N/AN/A
#6
$54.2M2169%N/AN/A
#7
$12M48N/AN/AN/A
#8
$10M405%N/AN/A
#9
$30.1M12022%N/AN/A
#10
$14.1M562%N/AN/A
Add Company

What Is Intersect ENT?

Intersect ENT (Nasdaq:XENT) is a medical technology company dedicated to advancing the treatment of ear, nose and throat (ENT) conditions through evidence-based innovation, providing physicians with solutions to overcome clinical challenges and improve the quality of life for patients. For additional information on the company or the products including risks and benefits please visit www.intersectENT.com

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals

$167.8M

Total Funding

161

Number of Employees

$112.4M

Revenue (est)

-8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Intersect ENT News

2022-04-17 - Intersect ENT (NASDAQ:XENT) Stock Rating Lowered by ...

Intersect ENT (NASDAQ:XENT) Stock Rating Lowered by StockNews.com. Posted by admin on Apr 26th, 2022. Share on Twitter Share on Facebook Share on LinkedIn...

2022-04-13 - Medtronic's planned purchase of Intersect ENT said expected ...

Medtronic's (NYSE:MDT) planned purchase of Intersect ENT (NASDAQ:XENT) is now likely to close in May instead of this month.

2021-09-20 - Intersect ENT : Understanding the Difference between COVID-19 Symptoms and Sinus Disease World Sinus Health Awareness Day 2021

September 20, 2021-Alexandria, Virginia-The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS), in partnership with Intersect ENT, Inc., launched a public education campaign that provides clinically-developed information by experts in the field aimed at helping people better unde ...

2021-08-06 - Intersect ENT : Medtronic to Acquire Intersect ENT

DUBLIN and MENLO PARK, Calif., Aug. 6, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has entered into a definitive agreement with Intersect ENT (NASDAQ: XENT), a global ear, nose, and throat (ENT) medical technology leader dedicat ...

2014-07-14 - Intersect ENT sets terms for $65M IPO

Intersect ENT said today that it hopes to raise as much as $65 million in an initial public offering of 5 million shares. Intersect, which makes drug-eluting devices designed to treat ear, nose & throat conditions, said it plans to price the shares at $11 to $13 apiece, meaning the offering cou ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$26M163N/AN/A
#2
$18.6M16927%N/A
#3
$42.7M17024%$145.6M
#4
$27.3M171N/AN/A
#5
$47.6M1738%N/A

Intersect ENT Funding

DateAmountRoundLead InvestorsReference
2008-06-06$20.0MBPTV SciencesArticle
2010-11-03$30.0MUndisclosedArticle
2013-02-26$30.0MDNorwest Venture PartnersArticle